UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: March 31,September 30, 2023

 

or

 

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

Commission File Number: 000-52759

 

BESPOKE EXTRACTS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada 20-4743354
(State or other jurisdiction 
of incorporation)
 (IRS Employer 
Identification No.)

 

12001 E. 33rd Avenue,33rd Street Unit O

Aurora, CO 80010

(Address of principal executive offices)

 

855-633-3738

(Registrant’s telephone number, including area code)

 

 

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months, and (2) has been subject to such filing requirements for the past 90 days. Yes  No 

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
 Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

 

As of July 14, 2023,January 16, 2024, there were 10,168,220 shares outstanding of the registrant’s common stock, par value $0.001.

 

 

 

 

 

 

TABLE OF CONTENTS

 

  Page No. 
   
PART I - FINANCIAL INFORMATION1
Item 1.Financial Statements1
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations16
Item 3.Quantitative and Qualitative Disclosures About Market Risk1819
Item 4Controls and Procedures1820
   
PART II - OTHER INFORMATION1921
Item 1.Legal Proceedings1921
Item 1A.Risk Factors1921
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds1921
Item 3.Defaults Upon Senior Securities1921
Item 4.Mine Safety Disclosures1921
Item 5.Other Information1921
Item 6.Exhibits1921

 

i

 

 

PART I

 

Item 1. Financial Statements. 

 

Bespoke Extracts, Inc.

Consolidated Balance Sheets

 

  March 31,  December 31, 
  2023  2022 
       
Assets      
Current assets      
Cash $4,365  $24,433 
Accounts receivable  46,483   - 
Prepaid stock awards  58,569   80,113 
Prepaid expense  26,356   7,186 
Inventory, net  13,010   - 
Total current assets  148,783   111,732 
         
Furniture and equipment  48,162   9,947 
License  10,000     
Right of Use Asset  259,564   275,912 
Deposits  12,000   12,000 
Total assets $478,509  $409,591 
         
Liabilities and Stockholders’ Deficit        
Current liabilities        
Accounts payable and accrued liabilities $492,074  $295,818 
Inventory earn-out  -   90,000 
Note payable - related party  692,500   415,500 
Operating lease liability  64,330   64,330 
Total current liabilities  1,248,904   865,648 
         
Long-Term Operating Lease Liability  199,889   216,039 
Total liabilities  1,448,793   1,081,687 
         
Commitments and contingencies (Note 10)        
         
Stockholders’ Deficit        
Preferred Stock, $0.001 par value, 50,000,000 shares authorized, 1 share designated;  1 share issued and outstanding as of March 31, 2023 and December 31, 2022, respectively, stated value $24,000  -   - 
Common stock, $0.001 par value: 3,000,000,000 authorized; 10,168,220 and 9,945,977 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively  10,166   9,944 
Common stock to issue 6,478 shares  -   - 
Additional paid-in capital  23,343,968   23,201,758 
Accumulated deficit  (24,324,418)  (23,883,798)
Total stockholders’ deficit  (970,284)  (672,096)
Total liabilities and stockholders’ deficit $478,509  $409,591 

  September 30,  December  31, 
  2023  2022 
       
Assets      
Current assets      
Cash $-  $24,433 
Accounts receivable, net  45,950   - 
 Prepaid stock awards  14,762   80,113 
Prepaid expense  10,695   7,186 
Inventory, net  25,557   - 
Total current assets  96,964   111,732 
         
Furniture and equipment  42,764   9,947 
License  10,000   - 
Right of Use Asset  226,381   275,912 
Deposits  12,000   12,000 
Total assets $388,109  $409,591 
         
Liabilities and Stockholders’ Equity        
Current liabilities        
Cash overdraft $2,949  $- 
Accounts payable and accrued liabilities  828,069   295,818 
Inventory earn-out  -   90,000 
Deferred revenue  2,936   - 
Note payable - related party  26,997   415,500 
Operating lease liability  64,330   64,330 
Total current liabilities  925,281   865,648 
         
Note payable - related party  849,500   - 
Long-Term Operating Lease Liability  167,101   216,039 
Total liabilities  1,941,882   1,081,687 
         
Commitments and contingencies (Note 10)        
         
Stockholders’ Deficit        
Preferred stock, par value $0.001, 50,000,000 shares authorized, 1 share issued and outstanding as of September 30, 2023 and December 31,2022, respectively  -   - 
Series C Convertible Preferred Stock, $0.001 par value, 1 share designated;  1 share issued and outstanding as of Sepember 30, 2023 and December 31, 2022, respectively, stated value $24,000.  -   - 
Common stock, $0.001 par value: 3,000,000,000 authorized; 10,168,220 and 9,946,067 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively  10,166   9,944 
Common stock to issue 6,478 shares  -   - 
Additional paid-in capital  23,533,615   23,201,758 
Accumulated deficit  (25,097,554)  (23,883,798)
Total stockholders’ deficit  (1,553,773)  (672,096)
Total liabilities and stockholders’ deficit $388,109  $409,591 

 

The accompanying notes are an integral part of these consolidated financial statements.

 


 

Bespoke Extracts, Inc.Inc

Consolidated Statements of Operations

(Unaudited)

 

  For the three months ended
March 31,
 
  2023  2022 
       
Sales $89,016  $3,061 
Cost of products sold  78,667   847 
Gross Profit  10,349   2,214 
         
Operating expenses:        
Selling, general and administrative expenses  374,515   897,534 
Professional fees  61,204   54,355 
Consulting  18,000   23,000 
Total operating expenses  453,719   974,889 
         
Loss from operations  (443,370)  (972,675)
         
Other income / (expenses)        
Interest income  2,750   181 
Interest expense  -   - 
Total other (expense) / income  2,750   181 
         
Loss before income tax  (440,620)  (972,494)
Provision for income tax  -   - 
Net Loss $(440,620) $(972,494)
         
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING        
Basic and Diluted  10,107,108   6,992,070 
         
NET LOSS PER COMMON SHARE OUTSTANDING        
Basic and Diluted $(0.04) $(0.14)

  For the three months ended September 30,  For the nine months ended September 30, 
  2023  2022  2023  2022 
             
Sales $244,408  $-  $521,671  $3,407 
Cost of products sold  146,000   65   341,878   47,580 
Gross Profit  98,408   (65)  179,793   (44,173)
                 
Operating expenses:                
Selling, general and administrative expenses  347,717   1,069,487   1,179,598   2,861,938 
Professional fees  46,883   29,270   171,259   119,118 
Consulting  -   35,750   36,000   94,250 
Total operating expenses  394,600   1,134,507   1,386,857   3,075,306 
                 
Loss from operations  (296,192)  (1,134,572)  (1,207,064)  (3,119,479)
                 
Other income / (expenses)                
Interest expense  (5,337)  -   (6,692)  - 
Interest income  -   447       878 
Total other (expense) / income  (5,337)  447   (6,692)  878 
                 
Loss before income tax  (301,529)  (1,134,125)  (1,213,756)  (3,118,601)
Provision for income tax  -   -   -   - 
Net Loss $(301,529) $(1,134,125) $(1,213,756) $(3,118,601)
                 
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING                
Basic and Diluted  10,168,220   8,353,245   10,165,778   7,724,148 
                 
NET LOSS PER COMMON SHARE OUTSTANDING                
Basic and Diluted $(0.03) $(0.14) $(0.12) $(0.40)

 

The accompanying notes are an integral part of these consolidated financial statements.

 


 

 

Bespoke Extracts, Inc.Inc

Consolidated Statement of Stockholders Equity / (Deficit)

For The three and nine months ended March 31,September 30, 2023 and March 31,September 30, 2022

 

  Series C                      
  Preferred  Preferred  Common  Common  Additional  Common Stock  Common Stock       
  Shares  Par  Shares  Par  Paid-in  Shares  to be issued  Accumulated    
  Outstanding  Amount  Outstanding  Amount  Capital  to be Issued  Par Amount  Deficit  Total 
                            
Balance  December 31, 2021             1  $            -   8,141,965  $8,142  $21,741,403   6,478  $7,987  $(19,767,571) $1,989,961 
                                     
Payment of capital contribution  -   -   -   -   4,792   -   -   -   4,792 
                                     
Stock based compensation and stock option expense  -   -   -   -   727,606   -   -   -   727,606 
                                     
Common stock issued for cash  -   -   876,667   877   196,373   -   -   -   197,250 
                                     
Net loss for the three months ended March 31, 2022  -   -   -   -   -   -   -   (972,494)  (972,494)
Balance March 31, 2022  1  $-   9,018,632  $9,019  $22,670,174  $6,478  $7,987  $(20,740,065) $1,947,115 
                                     
Balance  December 31, 2022  -  $-   9,945,997  $9,944  $23,201,758  $-  $-  $(23,883,798) $(672,096)
                                     
Purchase of Wonderleaf  -   -   222,223   222   49,778   -   -   -   50,000 
                                     
Stock option expense  -   -   -   -   92,432   -   -   -   92,432 
                                     
Net loss for the three months ended March 31, 2023  -   -   -   -   -   -   -   (440,620)  (440,620)
Balance March 31, 2023  1  $-   10,168,220  $10,166  $23,343,968  $-  $-  $(24,324,418) $(970,284)

   Series C                             
   Preferred Shares Outstanding   Preferred Par Amount   Common Shares Outstanding   Common Par
Amount
   Additional Paid-in Capital   Common Stock
Shares to be Issued
   Common Stock
to be issued Par Amount
    Accumulated
Deficit
   Total 
                                     
Balance  June 30, 2022  1  $-   9,672,854  $9,673  $23,564,461   6,478  $7,987  $(21,752,047) $1,830,074 
                                     
Stock based compensation and stock option expense  -   -   -   -   170,682   -   -   -   170,682 
                                     
Common stock issued for cash  -   -   266,667   267   682,820   -   -   -   683,087 
                                     
Net loss for the three months ended September 30, 2022  -   -   -   -   -   -   -   (1,134,125)  (1,134,125)
Balance  September 30, 2022  1  $-   9,939,521  $9,940  $24,417,963   6,478  $7,987  $(22,886,172) $1,549,718 

  Series C                      
  Preferred Shares Outstanding  Preferred Par Amount  Common Shares Outstanding  Common Par
Amount
  Additional Paid-in Capital  Common Stock
Shares to be Issued
  Common Stock
to be issued Par Amount
  Accumulated
Deficit
  Total 
                            
Balance June 30, 2023         1  $          -   10,168,220  $10,166  $23,436,312  $              -  $              -  $(24,796,025) $(1,349,547)
                                     
Stock based compensation and stock option expense  -   -   -   -   97,303   -   -   -   97,303 
                                     
Net loss for the three months ended September 30, 2023  -   -   -   -   -   -   -   (301,529)  (301,529)
Balance  September  30, 2023  1  $-   10,168,220  $10,166  $23,533615  $-  $-  $(25,097,554) $(1,553,773)

3

  Series C                      
  Preferred Shares Outstanding  Preferred Par
Amount
  Common Shares Outstanding  Common Par
Amount
  Additional Paid-in Capital  Common Stock
Shares
to be Issued
  Common Stock
to be issued Par Amount
   Accumulated
Deficit
  Total 
                            
Balance  December 31, 2021  1  $-   8,141,965  $8,142  $21,741,403   6,478  $7,987  $(19,767,571) $1,989,961 
                                     
Payment of capital contribution  -   -   -   -   4,792   -   -   -   4,792 
                                     
Stock based compensation and stock option expense  -   -   -   -   1,646,030   -   -   -   1,646,030 
                                     
Common stock issued for services  -   -   266,667   267   682,819   -   -   -   683,086 
                                     
Common stock issued for cash  -   -   1,530,889   1,531   342,919   -   -   -   344,450 
                                     
Net loss for the nine months ended September 30, 2022  -   -   -   -   -   -   -   (3,118,601)  (3,118,601)
Balance  September 30, 2022  1  $-   9,939,521  $9,940  $24,417,963   6,478  $7,987  $(22,886,172) $1,549,718 

  Series C                      
  Preferred Shares Outstanding  Preferred Par
Amount
  Common Shares Outstanding  Common Par
Amount
  Additional Paid-in Capital  Common Stock
Shares
to be Issued
  Common Stock
to be issued Par Amount
   Accumulated
Deficit
  Total 
                            
Balance  December 31, 2022  1  $-   9,945,997  $9,944  $23,201,758  $-  $-  $(23,883,798) $(672,096)
                                     
Purchase Wonderleaf  -   -   222,223   222   49,778   -   -   -   50,000 
                                     
Stock based compensation and stock option expense  -   -   -   -   282,079   -   -   -   282,079 
                                     
Net loss for Nine Months ended September 30, 2023  -   -   -   -   -   -   -   (1,213,756)  (1,213,756)
Balance  September 30, 2023  1  $-   10,168,220  $10,166  $23,533,615  $-  $-  $(25,097,554) $(1,553,773)

 

The accompanying notes are an integral part of these consolidated financial statements.

 


 

 

Bespoke Extracts, Inc.Inc

Consolidated Statements of Cash Flows

(Unaudited)

 

 For the three months ended
March 31,
  

For the Nine months ended
September 30,

 
 2023  2022  2023  2022 
Cash flows from operating activities          
Net Loss $(440,620) $(972,494) $(1,213,756) $(3,118,601)
Adjustments to reconcile net loss to net cash used in operating activities                
Inventory reserve  40,393   -   40,393   46,825 
Depreciation  1,785   -   7,183   - 
Allowance for doubtful accounts  -   3,636 
Amortization of right of use asset, net  16,348   -   49,531   - 
Amortization expense for prepaid expenses for consulting shares  21,544   15,745   65,351   - 
Stock based compensation and stock option expense  92,432   727,606   282,079   2,329,116 
Changes in operating assets and liabilities:                
Accounts receivable  (46,483)  (64)  (45,950)  - 
Prepaid expenses  (19,170)  996   (3,509)  (4,047)
Inventory  (53,403)  355   (65,950)  - 
Interest receivable – Wonderleaf  -   (181)
Interest receivable - Wonderleaf  -   (431)
Deposits  -   (1,416)
Accounts payable and accrued liabilities  196,256   22,892   535,200   141,113 
Deferred revenue  2,936   - 
Operating lease liability  (16,150)  (14,648)  (48,938)  (855)
Net Cash (used in) operating activities  (207,068)  (219,793)  (395,430)  (604,660)
                
Cash flows from investing activities                
Advances to Wonderleaf  -   (6,443)  -   (12,000)
Note receivable Wonderleaf funded  -   (20,000)  -   (20,250)
Purchase of equipment  -   (7,202)  -   (7,202)
Net cash used in investing activities  -   (33,645)  -   (39,452)
                
Cash flow from financing activities                
Payment of capital contribution  -   4,792   -   4,791 
Payment of inventory earnout  

(90,000

)  
-

  (90,000)  - 
Proceeds from issuance of note payable - related party  277,000   -   434,000   160,000 
Proceeds from advances - related party  26,997   - 
Repayment of note payable - related party  -   (2,500)  -   (2,500)
Proceeds from issuance of units  -   197,250   -   344,450 
Net cash provided by financing activities  187,000   199,542   370,997   506,741 
                
Net increase / (decrease) in cash  (20,068)  (53,896)  (24,433)  (137,371)
Cash at beginning of period  24,433   148,227   24,433   148,227 
Cash at end of period $4,365  $94,331  $-  $10,856 
                
Supplemental disclosure of cash flow information                
Cash paid for interest $-  $-  $-  $- 
Cash paid for income taxes $-  $-  $-  $- 
                
Noncash investing and financing activities:                
Stock issued to Wonderleaf for fixed assets and license $50,000  $-  $50,000  $- 

  

The accompanying notes are an integral part of these consolidated financial statements.

 


 

 

BESPOKE EXTRACTS, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31,September 30, 2023

(Unaudited)

 

1. NATURE OF OPERATIONS, SIGNIFICANT ACCOUNTING POLICIES AND GOING CONCERN

 

Nature of Business Operations 

 

Bespoke Extracts, Inc. (the “Company”) is a Nevada corporation focused on operating in the regulated cannabis markets in the United States. Through Bespoke Colorado, we operate a marijuana infused products production facility in Aurora, Colorado.

  

On December 2, 2021, Bespoke Extracts Colorado, LLC (“Bespoke Colorado”), a newly formed wholly-owned subsidiary of the Company entered into an asset purchase agreement with WonderLeaf, LLC (“WonderLeaf”), and on December 7, 2021, Bespoke Colorado and WonderLeaf entered into an amendment to such asset purchase agreement (as amended, the “WonderLeaf Purchase Agreement”)... On January 3, 2023, the Company completed the acquisition of the WonderLeaf assets and the change of control was approved by the Colorado Marijuana Enforcement Division for 222,223 shares of common stock valued at $50,000, or $0.225 per share. At the time of acquisition Wonderleaf had no operations or no employees and was not considered a business. 

 

On February 2, 2022, the Company changed its fiscal year from August 31 to December 31.

 

Certain prior period amounts have been reclassified to conform to the current period presentation which include common stock and additional paid in capital.

 

Principles of Consolidation

 
The accompanying condensed consolidated unaudited financial statements include the accounts of Bespoke Extracts, Inc., and its wholly owned subsidiary Bespoke Extracts Colorado, LLC. All inter-company balances have been eliminated.

 

Going Concern

 

The accompanying condensed consolidated unaudited financial statements have been prepared assuming a continuation of the Company as a going concern. The Company had negative cash flows from operations of $207,068$395,430_ for the threenine months ended March 31,September 30, 2023, and a working capital deficit of $1,100,121$851,602 and accumulated deficit of $24,324,418$25,097,554, as of March 31,September 30, 2023. This raises substantial doubt about our ability to continue as a going concern for a period of one year from the date of these financial statements.

 

The Company’s ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. There is no assurance that this series of events will be satisfactorily completed.

 

Further, if we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our common stock. If additional financing is not available or is not available on acceptable terms, we will have to curtail or cease our operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue in existence. These financial statements do not include any adjustments that might arise from this uncertainty.

 


 

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the accompanying consolidated financial statements and accompanying notes. Significant estimates include the assumption used in the valuation of equity-based transactions, valuation of intangible assets, allowance for doubtful accounts and inventory valuation and reserves. Actual results could differ from those estimates. 

 

Cash and Cash Equivalents

 

Cash and cash equivalents include all highly liquid investments with original maturities of three months or less at the time of purchase. At March 31,September 30, 2023 and December 31, 2022, the Company did not have any cash equivalents. The Company did not have any cash in excess of FDIC limits of $250,000 at any single bank.

 

Fair Value of Financial Instruments

 

The carrying amounts of cash, accounts receivable, inventory, fixed assets, licenses, and other assets, accounts payable, accrued liabilities, note payable and convertible notenotes payable approximate their fair values as of March 31,September 30, 2023 and December 31, 2022, respectively, because of their short-term natures and the Company’s borrowing rate of interest.

 

Accounts Receivable

 

Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to repay their obligation. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. If market conditions decline, actual collection experience may not meet expectations and may result in decreased cash flows and increased bad debt expense.

 

The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 3014 or net 6030 days. Once collection efforts by the Company, and its collection agency are exhausted, the determination for charging off uncollectible receivables is made. At March 31,September 30, 2023 and December 31, 2022, the Company has recorded an allowance for doubtful accounts of $0 and $0, respectively.

 

Inventory, Net

 

Inventories are stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out basis and net realizable value. Net realizable value is defined as sales price less cost of completion, disposition and transportation and a normal profit margin. As of March 31,September 30, 2023 and December 31, 2022, inventory amounted to $13,010$25,557, and $0 net of reserves, respectively, which consisted of finished goods of $13,010$0 and $0, and raw materials of $0$25,557 and $0, respectively.


Property and equipment

Property and equipment is recorded at cost and capitalized from the initial date of service. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment is retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses other depreciation methods (generally accelerated) for tax purposes where appropriate. The estimated useful lives for significant property and equipment categories are as follows:

 

Schedule of Estimated useful Lives of Property and Equipment

Furniture and Equipment5 years

License

License represents the Colorado license for distributing cannabis. The license has an indefinite useful life and the Company will be amortized over its useful life.test annually for impairment.


 

Revenue Recognition

 

We account for revenue in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standard Codification Topic 606, “Revenue from Contracts with Customers”. Revenue is measured based on the amount of consideration that we expect to receive, reduced by discounts and estimates for credits and returns (calculated based upon previous experience and management’s evaluation). Outbound shipping charged to customers is recognized at the time the related merchandise revenues are recognized and are included in net revenues. Inbound and outbound shipping and delivery costs are included in cost of revenues.

 

Our products are sold directly to licensed marijuana dispensaries in Colorado. Revenue is recognized when control of the merchandise is transferred to the customer, which generally occurs upon shipment. Payment is typically due on the date of shipment [oror within 15 days].14 to 30 days.

 

At March 31,September 30, 2023, two customers amounted to 27.5%31.2% and 31.4% amounted,15.2%, or 58.9%46.4% of accounts receivable. During the year ended December 31, 2022 no customer amounted to over 10% of the total accounts receivable. During the three months ended March 31,September 30, 2023 three customersone customer amounted to 14.4%, 15.1% and 16.4%, or 45.9%25.8% of sales for the period. During the threenine months ended March 31,September 30, 2023 one customer amounted to 33.3% of sales for the period During the three and nine months ended September 30, 2022 no individual customer amounted to over 10% of tota1 sales.

Cash Overdrafts

Cash Overdrafts represent disbursements in excess of cash balances on hand.

Deferred Revenue

Deferred Revenue represents serviced that was paid for but not delivered to the customer as of September 30, 2023.

 

Stock Based Compensation

 

Stock options and warrants issued to consultants and other non-employees as compensation for services provided to the Company are accounted for based on the fair value of the services provided or the estimated fair market value of the option or warrant, whichever is more reliably measurable, and in accordance with FASB ASC 718, Compensation-Stock Compensation, including related amendments and interpretations.

 

Reclassification

 

Prior gross prepaid stock compensation and additional paid in capital presented in the 10Q for the period end March 31,September 30, 2022 have been reclassified to conform with the financials filed in the December 31, 2022 10K.

 

Net Income / (Loss) per Share

 

Basic income / (loss) per share amounts are computed based on net income / (loss) divided by the weighted average number of common shares outstanding. Diluted earnings per share reflect the potential dilution that could occur if potentially dilutive securities were exercised or converted to common stock. The dilutive effect of options and warrants and their equivalent is computed by application of the treasury stock method and the effect of convertible securities by the “if converted” method. The effect of 219,55629,876 warrants and 1,023,8421,023,341 options is anti-dilutive for the three and nine months ended March 31,September 30, 2023 as they are not in the money. The effect of 562.967 warrants and 1,022,8421,023,842 options is anti-dilutive for the three and nine months ended March 31,September 30, 2022 as they are not in the money. 

 

Reverse Stock Split


 

On December 5, 2022 the Company approved an amendment to its articles of incorporation to effect a 45-to-1 reverse split of our common stock effective January 13, 2023. All prior equity amounts have been presented to reflect this split.

 

Recent accounting pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date.

 


Income Taxes

 

We utilize the asset and liability method of accounting for income taxes. We recognize deferred tax liabilities or assets for the expected future tax consequences of temporary differences between the book and tax basis of assets and liabilities. We regularly assess the likelihood that our deferred tax assets will be recovered from future taxable income. We consider projected future taxable income and ongoing tax planning strategies in assessing the amount of the valuation allowance necessary to offset our deferred tax assets that will not be recoverable. We have recorded and continue to carry a full valuation allowance against our gross deferred tax assets that will not reverse against deferred tax liabilities within the scheduled reversal period. If we determine in the future that it is more likely than not that we will realize all or a portion of our deferred tax assets, we will adjust our valuation allowance in the period we make the determination. We expect to provide a full valuation allowance on our future tax benefits until we can sustain a level of profitability that demonstrates our ability to realize these assets.

 

2. ASSET PURCHASE AGREEMENT

 

On January 3, 2023, the Company completed the acquisition of the WonderLeaf assets for 222,223 shares of common stock valued at $50,000, or $0.225 per share. At the time of acquisition Wonderleaf had no operations or no employees and was not considered a business. 

 

Pursuant to ASU 2017-01 and ASC 805, the Company analyzed the business of Wonderleaf to determine if the Company acquired a business or acquired assets. Based on this analysis, the Company determined that it acquired assets. No goodwill was recorded since the purchase was accounted for as an asset purchase. In accordance with ASC 805, the fair value of the assets acquired is based on either the fair value of the consideration given or the fair value of the assets acquired, whichever is more clearly evident, and thus, more reliably measurable. The Company used the market price of the 222,223 common shares issued of $50,000 as the fair value of the assets acquired since this value was more clearly evident, and thus, more reliably measurable than the fair value of the license and fixed assets acquired.

 

Company management determined if the Company acquired a business or acquired assets. The FASB issued new guidance (ASU 2017-01) that changed the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. The guidance requires an entity to evaluate if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets; if so, the set of transferred assets and activities is not a business. The guidance also requires a business to include at least one substantive process and narrows the definition of outputs by more closely aligning it with how outputs are described in ASC 606. Under the new guidance, an entity first determines whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this threshold is met, the set is not a business. If it’s not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. Under the ASU, a set is not a business when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets.

 

Pursuant to 805-10-55-83, the Company first considered the guidance in paragraphs 805-10-55-5A through 55-5C. The identifiable assets that could be recognized in the purchase only included the license and fixed assets. Accordingly, the transaction was not considered a business.

 


The monetary value of the 222,223 shares is deemed by the Company to be $50,000 in accordance with Accounting Standards Codification (“ASC”) 805-50-30 “Business Combinations”, the Company determined that if the consideration paid is not in the form of cash, the measurement may be based on either (i) the cost which is measured based on the fair value of the consideration given or (ii) the fair value of the assets (or net assets) acquired, whichever is more clearly evident and thus more reliably measurable. No goodwill should be recorded since the WPA was accounting for as an asset purchase. The Company determined that the fair value of the common shares issued was a better indicator which is more reliably measurable.

 

The Company assigned a value of $10,000 to the licenses and $40,000 to the fixed assets acquired.

 

3. INVENTORY EARN-OUT 

 

As described in Note 9, in exchange for cancellation of the debt owed under the Debenture, the Company transferred to the holder certain domain names and agreed to pay the holder, beginning December 1, 2021, and on a monthly basis through August 31, 2022, 40% of the operating profit generated from sale of the existing CBD inventory of the Company, and on August 31, 2022, to make a final payment equal to an amount of $75,000 minus the total of the monthly payments made under the Inventory Earn Out. As of December 31, 2022 no amounts had been paid. The inventory earn-out agreement was amended on November 11, 2022 such that the final payment under the inventory earn out was increased to $90,000 (less any payments previously made) and was due February 28, 2023. During the threenine months ended March 31,September 30, 2023 the amount was paid.


 

4. NOTE RECEIVABLE 

 

On January 19, 2022 the Company loaned WonderLeaf $10,000, pursuant to a promissory note. The note bears interest at 5% annually and matures on January 18, 2023.

 

On February 8, 2022 the Company loaned WonderLeaf $10,000, pursuant to a promissory note. The note bears interest at 5% annually and matures on February 8, 2023.

 

On October 25, 2022 the Company loaned WonderLeaf $25,000, pursuant to a promissory note. The note bears interest at 5% annually and matures on February 8, 2023.

 

As of December 31, 2022 accrued interest on the notes receivable amounted to $931.

 

At December 31, 2022 the Company recorded a reserve of $45,931 for the promissory notes and accrued interest.

 

Note 5 – Furniture and equipment.

 

Machinery and equipment consisted of the following at:

 

Schedule of Machinery and Equipment

 

 March 31,
2023
 December 31,
2022
  September 30,
2023
  December 31,
2022
 
Furniture and equipment $2,745  $2,745  $2,745  $2,745 
Machinery and Equipment $47,202  $7,202  $47,202  $7,202 
Fixed assets, total $49,947  $9,947  $49,947  $9,947 
Total: accumulated depreciation $(1,785) $-  $(7,183) $- 
Fixed assets, net $48,162  $9,947  $42,764  $9,947 

 

Depreciation expense for the three and nine months ended March 31,September 30, 2023 and March 31,September 30, 2022 were $1,785$2,617, $7,183, $0 and $0 respectively.


 

6. NOTE PAYABLE – RELATED PARTY

 

During the threenine months ended March 31,September 30, 2023, Infinity Management, LLC an affiliate of Michael Feinsod, the Company’s chief executive officer, loaned the Company an additional $227,000.$434,000. On September 5, 2023 $849,500 of notes payable were converted into a 5% interest bearing note due June 30, 2025 (the “Infinity Note”). In addition, repayment of the Infinity Note will be due out of the proceeds of a new debt or equity capital raise with net proceeds of more than $2,000,000. As of March 31,September 30, 2023 and December 31, 2022 the amount owed Michael FeinsodInfinity Management, LLC is $692,500$885,454 and $415,500, respectively. All loans are payable upon demand.

During the nine month ended September 30, 2023 Infinity Management, LLC an affiliate of Michael Feinsod advanced the Company and additional $26,997.

   

7. LEASES

 

In connection with the WonderLeaf Purchase Agreement, Bespoke Colorado entered into a lease agreement (the “Lease”) with WL Holdings, Ltd. (“WL Holdings”) in December 2021. Pursuant to the Lease, Bespoke Colorado will lease from WL Holdings certain commercial space in Aurora, Colorado, where WonderLeaf’s business has been located, commencing upon signing of the Lease and Wonderleaf Purchase Agreement, for a term of five years, which Bespoke Colorado will have an option to renew for an additional five years. Monthly rent under the Lease will start at $6,000. The Lease grants the Company an option to purchase the property for $600,000. The Company has not decided whether it will exercise either option.

 

Supplemental balance sheet information related to leases was as follows:

 

Lease term and discount rate were as follows:

 

  March  31,September 30, 
  2023 
Weighted average remaining lease term (years)  3.693.19 
Weighted average discount rate  4%

 


The component of lease costs was as follows:

 

 Three Months ended
March  31,
  Nine months
ended
September 30,
 
 2023  2023 
Operating lease cost $19,093  $57,294 
Variable lease cost (1)  1,050   3,150 
Total lease costs $20,143  $60,444 

 

(1)Variable lease cost primarily relates to common area maintenance, property taxes and insurance on leased real estate.

 

Supplemental disclosures of cash flow information related to leases were as follows:

 

  March 31,September 30, 
  2023 
Cash paid for operating lease liabilities $         - 

 


Maturities of lease liabilities were as follows as of March 31,September 30, 2023:

 

  Operating 
  Leases 
2023 $56,700 
2024  75,915 
2025  79,380 
2026  72,765 
Thereafter  - 
Total undiscounted lease payments  284,760 
Less: Present value discount  (23,291)
Total Present value of lease liabilities $264,219 

  Operating 
  Leases 
2023 $16,641 
2024  75,915 
2025  79,380 
2026  72,765 
Thereafter  - 
Total undiscounted lease payments  244,701 
Less: Present value discount  (13,270)
Total Present value of lease liabilities $231,431 

 

Operating Leases Classification March 31,
2023
 
Right-of-use assets Right of use assets $259,564 
       
Current lease liabilities Current operating lease liabilities  64,330 
Non-current lease liabilities Long-term operating lease liabilities  199,889 
Total lease liabilities   $264,219 

Operating Leases Classification September 30,
2023
 
Right-of-use assets Right of use assets $226,381 
Current lease liabilities Current operating lease liabilities  64,330 
Non-current lease liabilities Long-term operating lease liabilities  167,101 
Total lease liabilities   $231,431 

 

8. EQUITY

 

Common Stock and Preferred Stock

 

On December 5, 2022 the Company approved an amendment to its articles of incorporation to effect a 45-to-1 reverse split of our common stock effective January 13, 2023. All prior amounts equity amounts have been presented to reflect this reverse split.

 


As of March 31,September 30, 2023 and December 31, 2022, the Company’s authorized capital stock consists of 3,000,000,000 shares of common stock, par value $0.001, and 50,000,000 shares of preferred stock, par value $0.001. 1,000 shares of preferred stock are designated as Series A Convertible Preferred Stock. No shares of Series A Preferred Stock are issued and outstanding as of March 31,September 30, 2023 and December 31, 2022, respectively. The Company’s Certificate of Designation of Series B Preferred Stock was withdrawn by the Company on JuneSeptember 30, 2020. 1 share of preferred stock is designated Series C Preferred Stock and is issued and outstanding as of March 31,September 30, 2023 and December 31, 2022, respectively. The Series C Preferred Stock has a stated value of $24,000 and entitles the holder to 51% of the total voting power of the Company’s stockholders. The Company may, in its sole discretion, redeem the Series C Preferred Stock at any time for a redemption price equal to the stated value. Upon payment of the redemption price by the Company, the Series C Preferred Stock will revert to the status of authorized but unissued preferred stock. 

 

On January 3, 2023, the Company completed the acquisition of the WonderLeaf assets for 222,223 shares of common stock valued at $50,000, or $0.225 per share.

 

On December 14, 2021, the board of directors of the Company adopted the Company’s 2021 Equity Incentive Plan (the “2021 Plan”), pursuant to which up to an aggregate of 6,666,667 shares of common stock are available for issuance. Awards under the plan may include options (including incentive stock options and non-qualified stock options), stock appreciation rights, restricted stock, restricted stock units, performance share awards, or other equity-based awards, each as defined under the 2021 Plan. Options awarded under the 2021 Plan are to have an exercise price of not less than 100% of the fair market value of the common stock on the grant date and a term of not more than ten years from the option grant date.

 

On December 14, 2021, the Company entered into an employment agreement with Hunter Garth. Pursuant to the employment agreement, Mr. Garth will serve as the Company’s president and will receive a base monthly salary of $8,000. The Company also granted to Mr. Garth, pursuant to the Company’s 2021 Equity Incentive Plan, 500,000 shares of restricted common stock valued at $675,000 ($1.35 per share), which vested one year from the date of grant. During the year ended December 31, 2022 the Company recorded $675,000 a prepaid expenses associated with the stock based compensation. During the years ended December 31, 2022 and 2021 the amount was amortized $643,562 and $31,438, respectively.

 


On December 14, 2021, the Company entered into an employment agreement with Michael Feinsod, the Company’s chief executive officer and chairman. Pursuant to the employment agreement, Mr. Feinsod will continue to serve as the Company’s chief executive officer and chairman and will receive a base monthly salary of $10,000. The Company also granted to Mr. Feinsod, pursuant to the Company’s 2021 Equity Incentive Plan, 1,000,000 shares of restricted common stock valued at $1,350,000 ($1.35 per share), which vested one year from the date of grant. During the year ended December 31, 2022 the Company recorded $1,350,000 of prepaid expenses associated with the stock based compensation. During the years ended December 31, 2022 and 2021 the amount was amortized $1,287,123 and $62,877, respectively. As of December 31. 2022 and 2021 the Company recorded a prepaid stock award of $0 and $1,287,123, respectively.

 

During the year ended December 31, 2022, the Company entered into and closed securities purchase agreements with investors pursuant to which the Company issued and sold to the investors an aggregate of 1,530,897 shares of common stock and warrants to purchase an aggregate of 1,530,897 shares of common stock, for an aggregate purchase price of $344,450. The warrants expired June 30, 2023 and had an exercise price of $2.25.

 

Effective August 1, 2022, the Company issued an aggregate of 266,667 shares of common stock to employees and consultants for services, including 155,556 shares that vest immediately, 55,556 shares that vested one year from the grant date, and 55,556 shares that will vest two years from the grant date. During the year ended December 31, 2022 the Company recorded an expense $1,104,928. For the three and nine months ended March 31,September 30, 2023 the Company recorded an expense of $21,544.$21,544 and $43,328, respectively. As of March 31,September 30, 2023 and December 31, 2022 the Company had a prepaid stock award of $58,569$38,785 and $80,113.

 

Effective August 1, 2022, the Company issued an aggregate of 266,667 shares of common stock to employees and consultants for services, including 155,556 shares that vest immediately, 55,556 shares that vested one year from the grant date, and 55,556 shares that will vest two years from the grant date. During the year ended December 31, 2022 the Company recorded an expense of $1,104,928. For the three and nine months ended September 30, 2023 the Company recorded an expense of $21,544 and $43,328, respectively. As of September 30, 2023 and December 31, 2022 the Company had a prepaid stock award of $38,785 and $80,113.


 

Warrants

 

During the four months ended December 31, 2021, the Company entered into and closed securities purchase agreements with investors pursuant to which the Company issued and sold to the investors an aggregate of 50,000,000 shares of common stock and warrants to purchase an aggregate of 12,500,000 shares of common stock, for an aggregate purchase price of $250,000 with offering costs of $10,000 for legal expenses. The warrants had a term of one year and an exercise price of $2.25.

 

During the year ended December 31, 2022, the Company entered into and closed securities purchase agreements with investors pursuant to which the Company issued and sold to the investors an aggregate of 1,530,887 shares of common stock and warrants to purchase an aggregate of 382,722 shares of common stock, for an aggregate purchase price of $344,450. The warrants expired June 30, 2023 and had an exercise price of $2.25.

 

The following table summarizes the warrant activities during the threenine months ended March 31,September 30, 2023:

 

  Number of
Warrants
  Weighted-
Average
Exercise
Price Per
Share
  Weighted-
Average
Remaining
Life
 
Outstanding at August 31, 2022  438,723   5.03   0.36 
Granted  -   -   - 
Canceled or expired  (219,167)  2.45   - 
Outstanding at March 31, 2023  219,556  $7.81   0.33 years 
Exercisable at March 31, 2023  219,556  $7.81   0.33 years 
Intrinsic value at March 31, 2023     $-     
  Number of
Warrants
  Weighted-
Average
Exercise
Price Per
Share
  Weighted-
Average
Remaining
Life
 
Outstanding at December 31, 2022  438,723   5.03   0.36 
Granted  -   -   - 
Canceled or expired  (408,847)  0.95   - 
Outstanding at September 30, 2023  29,876  $25.24   1.46 years 
Exercisable at September 30, 2023  29,875  $25,.24   1.46 years 
Intrinsic value at September 30, 2023     $-     

 


Options

 

On December 14, 2021, the Company entered into an employment agreement with Hunter Garth, wherein the Company granted to Mr. Garth, pursuant to the Company’s 2021 Equity Incentive Plan, ten-year options to purchase 333,333 shares of common stock at an exercise price of $2.70 (representing a 120% premium over the closing price of the common stock on December 13, 2021). One-third of the options will vest on each yearly anniversary of the date of grant. The options were valued at $450,000 using a Black-Scholes pricing model. During the three and nine months ending March 31,September 30, 2023 and 2022 the Company recorded $30,811, $92,433, $67,797 and $97,797$203,391 respectively of expenses associated with the vesting of these stock options. (See notes 9 and 10).

 

On December 14, 2021, the Company entered into an employment agreement with Michael Feinsod, wherein the Company granted to Mr. Feinsod, pursuant to the Company’s 2021 Equity Incentive Plan, ten-year options to purchase 666,667 shares of common stock at an exercise price of $2.70 (representing a 120% premium over the closing price of the common stock on December 13, 2021). One-third of the options will vest on each yearly anniversary of the date of grant. The options were valued at $900,000 using a Black-Scholes pricing model. During the three and nine months ended March 31,September 30, 2023 and 2022 the Company recorded $61,621, $184,863, $135,594 and $135,594,$406,782, respectively of expenses associated with the vesting of these stock options. (See notes 9 and 10).

 

On December 14, 2021, the Company issued to a consultant options to purchase 22,222 shares of common stock at an exercise price of $1.35. The options vest over a period of 3 months and have a term of 10 years. The options were valued at $30,000 using a Black-Scholes pricing model. During the three and nine months ended March 31,September 30, 2023 and 2022 the Company recorded $0, $0, $0 and $24,900, respectively of expenses associated with the vesting of these stock options.

 

On August 17, 2023, the Company issued to several employees options to purchase 222,500 shares of common stock at an exercise price of $0.20. The options vest over a period of 12 months and have a term of 5 years. The options were valued at $44,306 using a Black-Scholes pricing model. During the three and nine months ended September 30, 2023 and 2022 the Company recorded $4,871 and $4,871, respectively of expenses associated with the vesting of these stock options


 

 

The following table summarizes the option activities during the fournine months ended December 31, 2021 and the year ended December 31, 2022:September 30, 2023:

 

 Number of
Options
  Weighted-
Average Exercise
Price Per
Share
  Weighted-
Average
Remaining
Life
  Number of
Options
  Weighted-
Average Exercise
Price Per
Share
  Weighted-
Average
Remaining
Life
 
Outstanding at December 31, 2022  1,023,842   2.67   8.95 years   1,023,842  $2.67   8.95 years 
Granted  -   -       222,500  $0.20   4.88 years  
Canceled or expired  -   -       -   -     
Exercised  -   -       -   -     
Outstanding at March 31, 2023  1,023,842  $2.67   8.71 years 
Exercisable at March 31, 2023  357,174  $2.67   8.69 years 
Intrinsic value at March 31, 2023     $-     
Outstanding at September 30, 2023  1,246,341  $2.67   7.61 years 
Exercisable at September 30, 2023  357,174  $2.19   8.19 years 
Intrinsic value at September 30, 2023     $-     

 

The future expense as of March 31,September 30, 2023 is $420,381.$271,054.

 

9. RELATED PARTY TRANSACTIONS

  

On December 14, 2021, the Company entered into an employment agreement with Hunter Garth. Pursuant to the employment agreement, Mr. Garth will serve as the Company’s president and will receive a base monthly salary of $8,000. The Company also granted to Mr. Garth, pursuant to the Company’s 2021 Equity Incentive Plan, 500,000 shares of restricted common stock, which vested one year from the date of grant, and ten-year options to purchase 333,333 shares of common stock at an exercise price of $2.70 (representing a 120% premium over the closing price of the common stock on December 13, 2021). One-third of the options will vest on each yearly anniversary of the date of grant. In the event that Mr. Garth is terminated without cause or resigns with good reason (each as defined in the employment agreement), he will be entitled to his monthly base salary for twelve months following such termination.

 


On December 14, 2021, the Company entered into an employment agreement with Michael Feinsod, the Company’s chief executive officer and chairman. Pursuant to the employment agreement, Mr. Feinsod will continue to serve as the Company’s chief executive officer and chairman and will receive a base monthly salary of $10,000. The Company also granted to Mr. Feinsod, pursuant to the Company’s 2021 Equity Incentive Plan, 1,000,000 shares of restricted common stock, which vested one year from the date of grant, and ten-year options to purchase 666,667 shares of common stock at an exercise price of $2.70 (representing a 120% premium over the closing price of the common stock on December 13, 2021). One-third of the options will vest on each yearly anniversary of the date of grant. In the event that Mr. Feinsod is terminated without cause or resigns with good reason (each as defined in the employment agreement), he will be entitled to his monthly base salary for twelve months following such termination.

 


During the yearnine months ended December 31, 2022,September 30, 2023, Michael Feinsod, the Company’s chief executive officer, loaned the Company an additional $434,000. As of September 30, 2023 and December 31, 2022 the amount owed Michael Feinsod is $849,500 and $415,500, respectively. All loans are payable upon demand. On September 5, 2023 $849,500 of notes payable were converted into a 5% interest bearing note due June 30, 2025. The note contains provisions whereby it is intended to be subordinate to any senior secured debt the Company may incur while it is outstanding. In addition, repayment of the note will be due in full out of the proceeds of a new debtor equity capital raise with net proceeds of more than $2,000,000. (See Note 6.)

During the nine months ended September 30, 2023 Infinity Management, LLC an affiliate of Michael Feinsod advanced the Company $415,500 and was repaid $2,500 for operations. During the three months ended March 31, 2023 Michael Feinsod advanced an additional $277,000. The loans are non-interest bearing and payable upon demand.$26,997. (See Note 6.)

 

As of March 31,September 30, 2023 Michael Feinsod is owed a total of $105,000$165,000 of accrued salary and accounts payable of $78,936.$138,066.

 

10. COMMITMENTS AND CONTINGENCIES

 

In connection with a stock purchase agreement, on October 28, 2021, a convertible debenture with an original issue date of December 24, 2019, as amended by Amendment No. 1 thereto, dated May 28, 2020, Amendment No. 2 thereto, dated August 21, 2020, Amendment No. 3 thereto, dated December 10, 2020, Amendment No. 4 thereto, dated January 15, 2021, Amendment No. 5 thereto, dated April 2, 2021, and Amendment No. 6 thereto, dated August 2, 2021 (as amended, the “Debenture”) with an original principal amount of approximately $400,000 was terminated, and all amounts due and payable thereunder forgiven pursuant to a cancellation and satisfaction of debenture agreement entered into between the Company and the Debenture holder (the “Debt Cancellation Agreement”). In exchange for cancellation of the debt owed under the Debenture, the Company transferred to the holder certain domain names and agreed to pay the holder, beginning December 1, 2021, and on a monthly basis through August 31, 2022, 40% of the operating profit generated from sale of the existing CBD inventory of the Company (the “Inventory Earn Out”), and on August 31, 2022, to make a final payment equal to an amount of $75,000 minus the total of the monthly payments made under the Inventory Earn Out. The inventory earn-out agreement was amended on November 11, 2022 (see Note 3) such that the final payment under the inventory earn out was increased to $90,000 (less any payments previously made) and was due February 28, 2023. During the threenine months ended March 31,September 30, 2023 the amount was paid.

 


On December 14, 2021, the Company entered into an employment agreement with Hunter Garth. Pursuant to the employment agreement, Mr. Garth will serve as the Company’s president and will receive a base monthly salary of $8,000. The Company also granted to Mr. Garth, pursuant to the Company’s 2021 Equity Incentive Plan, 500,000 shares of restricted common stock, which vested one year from the date of grant, and ten-year options to purchase 333,333 shares of common stock at an exercise price of $2.70 (representing a 120% premium over the closing price of the common stock on December 13, 2021). One-third of the options will vest on each yearly anniversary of the date of grant. In the event that Mr. Garth is terminated without cause or resigns with good reason (each as defined in the employment agreement), he will be entitled to his monthly base salary for twelve months following such termination.

  

On December 14, 2021, the Company entered into an employment agreement with Michael Feinsod, the Company’s chief executive officer and chairman. Pursuant to the employment agreement, Mr. Feinsod will continue to serve as the Company’s chief executive officer and chairman and will receive a base monthly salary of $10,000. The Company also granted to Mr. Feinsod, pursuant to the Company’s 2021 Equity Incentive Plan, 1,000,000 shares of restricted common stock, which vested one year from the date of grant, and ten-year options to purchase 666,667 shares of common stock at an exercise price of $0.06 (representing a 120% premium over the closing price of the common stock on December 13, 2021). One-third of the options will vest on each yearly anniversary of the date of grant. In the event that Mr. Feinsod is terminated without cause or resigns with good reason (each as defined in the employment agreement), he will be entitled to his monthly base salary for twelve months following such termination.

 

On August 11, 2022, the Company and Bespoke Colorado entered into an asset purchase agreement with Osiris, LLC doing business as Best Day Ever (“BDE”) and Michael Gurtman. Pursuant to the purchase agreement, Bespoke Colorado agreed to purchase from BDE, and BDE agreed to sell to Bespoke Colorado, the assets of BDE, including certain licenses. The Company also agreed to assume certain leases, all as further set forth in the purchase agreement. As consideration for the acquisition of the assets, the Company agreed to issue 2,777,778 shares of common stock at the closing of the transaction. Closing of the purchase agreement was subject to receipt of certain governmental approvals and other customary closing conditions. The purchase agreement was terminated on November 18, 2022.

 

11. SUBSEQUENT EVENTS

 

Subsequent to March 31,September 30, 2023, , the Company’s chief executive officer, loaned the Company an additional $157,000.$33,000.

 


 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

We and our representatives may from time to time make written or oral statements that are “forward-looking,” including statements contained in this report and other filings with the SEC, reports to our stockholders and news releases. All statements that express expectations, estimates, forecasts or projections are forward-looking statements. In addition, other written or oral statements which constitute forward-looking statements may be made by us or on our behalf. Words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “project,” “forecast,” “may,” “should,” and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in or suggested by such forward-looking statements. We undertake no obligation to update or revise any of the forward-looking statements after the date of this report to conform forward-looking statements to actual results, except as may be required under applicable law. Important factors on which such statements are based are assumptions concerning uncertainties, including but not limited to, uncertainties associated with the following:

 

 Inadequate capital and barriers to raising the additional capital or to obtaining the financing needed to implement our business plans;

 

 Our failure to earn significant revenues or profits;

 

 Volatility, lack of liquidity or decline of our stock price;

 

 Potential fluctuation in quarterly results;

 

 Rapid and significant changes in markets; and

 

 Insufficient revenues to cover operating costs.costs; and

The effect of the COVID-19 pandemic on our operations, including as it may limit access to our facilities, customers, management, and professional advisors, and negatively impact demand for our products, and ability to raise capital on acceptable terms or at all.

 

The following discussion should be read in conjunction with the financial statements and the notes thereto which are included in this report.

 

Overview

 

Through our wholly-owned subsidiary, Bespoke Extracts Colorado, LLC, we operate a marijuana infused products manufacturing facility in Colorado.

 

In November 2021, new management of the Company was appointed and the Company began to focus on other complimentary lines of business to its CBD offerings. Under our new management team, we plan to expand the Company’s focus to regulated cannabis markets in the United States.

 

On December 2, 2021, Bespoke Extracts Colorado, LLC, a newly formed wholly-owned subsidiary of the Company entered into an asset purchase agreement with WonderLeaf, and on December 7, 2021, Bespoke Colorado and WonderLeaf entered into an amendment to such asset purchase agreement (as amended, the “WonderLeaf Purchase Agreement”). Pursuant to the Wonderleaf Purchase Agreement, Bespoke Colorado agreed to purchase from WonderLeaf, and WonderLeaf agreed to sell to Bespoke Colorado, certain assets of WonderLeaf, including a license to manufacture marijuana-infused products, existing inventory, and extraction equipment and ancillary items, all as further set forth in the WonderleafWonderLeaf Purchase Agreement, for a purchase price of $50,000, to be paid in shares of common stock of the Company. The Company issued a total of 222,223 shares of common stock ($0.225 per share), the fair market value on the date of issuance.

 


 

 

Results of Operations for the three months ended March 31,September 30, 2023 and March 31,September 30, 2022

 

Sales

 

Sales during the three months ended March 31,September 30, 2023 were $89,016$244,408 compared to $3,061$0 for the three months ended March 31,September 30, 2022. The increase in sales was a direct result of the products we are now producing after the purchase of Wonderleaf.WonderLeaf. The increase in sales was due to direct sales of pre-rolled joints to licensed dispensaries in Colorado.

 

Cost of Goods Sold

 

Cost of goods sold for the three months ended March 31,September 30, 2023 was $78,667$146,000 compared to $847$0 for the three months ended March 31,September 30, 2022. The increase was a direct result of the increase in sales. The increase in cost of sales was due to increases in purchases of raw materials, packaging, and labor associated with the production of pre-rolled joints.

 

Operating Expenses

 

Selling, general and administrative expenses for the three months March 31,September 30, 2023 and March 31,September 30, 2022 were $375,415$347,717 and $897,534,$1,069,487, respectively. The decrease was mainly attributable to reduced stock-based compensation of $92,432 for the three months ended March 31, 2023 compare to $727,606 for the three months ended March 31, 2022$763,158 and werewas partially offset by increase in salaries.increased salary expenses. Professional fees were $61,240$46,833 and $54,355,$29,270, respectively for the three months ended March 31,September 30, 2023 and March 31,September 30, 2022. Consulting expenses were $0 and $35,750, for the three months ended September 30, 2023 and September 30, 2022, respectively.

Other Income / (Expenses)

During the three months ended September 30, 2023 and September 30, 2022 there were $(5,377) and $447, respectively associated with interest expense on loans and interest income on the note receivable from WonderLeaf.

Net Loss

For the reasons stated above, our net loss for the three months ended September 30, 2023 was $301,529, or $0.03 per share, compared to a net loss for the three months ended September 30, 2022 of $1,134,125 or $0.14 per share

Results of Operations for the nine months ended September 30, 2023 and September 30, 2022

Sales

Sales during the nine months ended September 30, 2023 were $524,671 compared to $3,407 for the nine months ended September 30, 2022.

The increase in sales was a direct result of the products we are producing after the purchase of WonderLeaf. The increase in sales was due to direct sales of pre-rolled joints to licensed dispensaries in Colorado. 

Cost of Goods Sold

Cost of goods sold for the nine months ended September 30, 2023 was $341,878 compared to $47,580 for the nine months ended September 30, 2022. The increase was a direct result of the increase in sales. The increase in cost of sales was due to increases in purchases of raw materials, packaging, and labor associated with the production of pre-rolled joints.

Operating Expenses

Selling, general and administrative expenses for the nine months September 30, 2023 and September 30, 2022 were $1,179,598 and $2,861,938, respectively. The decrease was mainly attributable to a reduction of stock-based compensation of $2,047,237 and partially offset by increased payroll expenses. Professional fees were $171,259 and $119,118, respectively for the nine months ended September 30, 2023 and September 30, 2022. The increase in expenses was due to increased legal and accounting fees associated with the pending WonderLeaf, LLC acquisition. Consulting expense was $18,000$36,000 and $23,000,$94,250, for the threenine months ended March 31,September 30, 2023 and March 31,September 30, 2022, respectively.


Other Income/ (Expenses)

During the nine months ended September 30, 2023 and September 30, 2022 there were $(6,692) and $878, respectively associated with interest expense on loans and interest income on the note receivable from WonderLeaf.

 

Net Loss

 

OurFor the reasons stated above, our net loss for the threenine months ended March 31,September 30, 2023 was $440,620,$1,213,756, or $0.04$0.12 per share, compared to a net loss for the threenine months ended March 31,September 30, 2022 of $972,494,$3,118,601, or $0.14$0.40 per share.share

 

Investing Activities

 

During the threenine months ended March 31,September 30, 2023 and September 30, 2022 the Company loaned WonderleafWonderLeaf a total of $0 and $20,000, respectively pursuant to promissory notes, advanced Wonderleaf $6,443WonderLeaf $12,000 and purchased $7,202 of equipment.

 

Liquidity and Capital Resources

 

As of March 31,September 30, 2023, we had cash deficit of $4,365.$2,949. Net cash used in operating activities for the threenine months ended March 31,September 30, 2023 was $207,068.$398,379. Our current liabilities as of March 31,September 30, 2023 were $1,248,904$925,281 and consisted of accounts payable and accrued liabilities of $492,074,$828,069, and current portion of lease liability of $64,330 and notes payable related party of $692,500.$26,997. As of March 31,September 30, 2022, we had cash of $94,331.$10,856. Net cash used in operating activities for the threenine months ended March 31,September 30, 2022 was $219,793. Our current liabilities as of March 31, 2022 were $241,900 and consisted of accounts payable and accrued liabilities of $105,621, an inventory earn-out of $75,000 and current portion of lease liability of $61,279. $604,660.

 

During the threenine months ended March 31,September 30, 2023, the Company borrowed an additional $277,000 from$434,000 in a related party and repaid $90,000 owed for an inventory earnout. During the three months ended March 31, 2022, the Company repaid $2,500 of a noteNote payable from a related party. In addition, the Company raised a total of $197,250 from the sale of common stock and warrants.

 

The unaudited condensed consolidated financial statements included in this report have been prepared assuming a continuation of the Company as a going concern. The Company had negative cash flows from operations for the threenine months ended March 31,September 30, 2023 and the year ended December 31, 2022 and had a working capital deficit at March 31,September 30, 2023 and December 31, 2022. This raises substantial doubt about our ability to continue as a going concern.

 

We have not generated positive cash flows from operating activities. Our primary source of capital has been from the sale of equity and convertible debt securities. Our primary use of capital has been for professional fees and selling, general and administrative costs. We have no committed sources of capital and will need to raise additional capital to continue and expand our operations. Additional capital may not be available on terms acceptable to us, or at all.

 

In addition, the COVID-19 pandemic may negatively affect our operations, including by limiting access to our facilities, customers, management, and professional advisors, and by causing delays and constraints in manufacturing and shipping of our products. These factors, in turn, may negatively impact our operations, financial condition and demand for our products, and our ability to raise capital on acceptable terms, or at all.

 


 

 

Off-Balance Sheet Arrangements

 

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Critical accounting policies and estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenue and expenses during the reported periods. The more critical accounting estimates include estimates related to revenue recognition and accounts receivable allowances. We also have other key accounting policies, which involve the use of estimates, judgments and assumptions that are significant to understanding our results, which are described below and in Note 1 to our financial statements appearing elsewhere in this report.  

Accounts Receivable

Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to repay their obligation. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. If market conditions decline, actual collection experience may not meet expectations and may result in decreased cash flows and increased bad debt expense.

Inventory

Inventories are stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out basis and net realizable value. Net realizable value is defined as sales price less cost of completion, disposition and transportation and a normal profit margin.

Income Taxes

We utilize the asset and liability method of accounting for income taxes. We recognize deferred tax liabilities or assets for the expected future tax consequences of temporary differences between the book and tax basis of assets and liabilities. We regularly assess the likelihood that our deferred tax assets will be recovered from future taxable income. We consider projected future taxable income and ongoing tax planning strategies in assessing the amount of the valuation allowance necessary to offset our deferred tax assets that will not be recoverable. We have recorded and continue to carry a full valuation allowance against our gross deferred tax assets that will not reverse against deferred tax liabilities within the scheduled reversal period. If we determine in the future that it is more likely than not that we will realize all or a portion of our deferred tax assets, we will adjust our valuation allowance in the period we make the determination. We expect to provide a full valuation allowance on our future tax benefits until we can sustain a level of profitability that demonstrates our ability to realize these assets.

Stock Based Compensation

Stock options and warrants issued to consultants and other non-employees as compensation for services provided to the Company are accounted for based on the fair value of the services provided or the estimated fair market value of the option or warrant, whichever is more reliably measurable, and in accordance FASB ASC 718, Compensation-Stock Compensation, including related amendments and interpretations.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not required for smaller reporting companies.

 


Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Management of the Company conducted an evaluation of the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rule 13a-15(e) and Rule 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. The Company’s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Based on this evaluation, our management has concluded that the design and operation of our disclosure controls and procedures are not effective since the following material weaknesses exist:

 

 Our chief executive officer also functions as our principal financial officer. As a result, our officer may not be able to identify errors and irregularities in the financial statements and reports;

 

 We were unable to maintain full segregation of duties within our financial operations due to our reliance on limited personnel in the finance function. While this control deficiency did not result in any audit adjustments to our financial statements, it could have resulted in a material misstatement that might have been prevented or detected by a segregation of duties; and

 

 Documentation of all proper accounting procedures is not yet complete.

 

To the extent reasonably possible given our limited resources, we intend to take measures to cure the aforementioned weaknesses, including, but not limited to, increasing the capacity of our qualified financial personnel to ensure that accounting policies and procedures are consistent across the organization and that we have adequate control over financial statement disclosures.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting that occurred during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 


 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

We are not currently a party to, nor are any of our property currently the subject of, any material legal proceedings. 

 

Item 1A. Risk Factors.

 

Not required for smaller reporting companies. 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

No disclosure required. 

 

Item 5. Other Information.

 

None.

 

Item 6. Exhibits.

 

Exhibit No. Description
31.1 Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
32.1 Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
101.INS Inline XBRL Instance Document
101.SCH Inline XBRL Taxonomy Extension Schema Document.
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

*Filed herewith.

 

**Furnished herewith.

 


 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 BESPOKE EXTRACTS, INC.
   
Dated: July 14, 2023January 16, 2024By:/s/ Michael Feinsod
  

Michael Feinsod

Chief Executive Officer

  (Principal Executive Officer,
Principal Financial Officer and
Principal Accounting Officer)

 

 

2022

 

0001409197 bspk:TwentyTwentyOneEquityIncentivePlanMember bspk:MichaelFeinsodMember 2021-12-01 2021-12-13 iso4217:USD xbrli:shares